Stimulation of vitamin A1 acid signaling by the HIV protease inhibitor indinavir

被引:58
作者
Lenhard, JM
Weiel, JE
Paulik, MA
Furfine, ES
机构
[1] Glaxo Wellcome Inc, Dept Metab Dis, Res Triangle Pk, NC 27709 USA
[2] Glaxo Wellcome Inc, Dept Mol Biochem, Res Triangle Pk, NC 27709 USA
关键词
adipogenesis; dyslipidemia; lipodystrophy; indinavir; retinoic acid; toxicity;
D O I
10.1016/S0006-2952(00)00246-X
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
HIV protease inhibitors (PIs) are effective drugs for the treatment of AIDS. However, PI therapy is sometimes associated with side-effects including increased plasma lipids and altered body fat distribution, although fat redistribution may occur in some patients not treated with PIs. Overdosage with vitamin A, acid (all-trans-retinoic acid, ATRA) or its metabolites may cause similar changes in lipid metabolism Moreover, the PI indinavir and retinoids have been associated with nail, skin, and hair defects, suggesting that indinavir and retinoids may exert their effects through similar molecular mechanisms. This hypothesis was tested by examining the effects of PIs on retinoid signaling in vitro. Mesenchymal stem cells (C3H10T1/2) were cultured in the presence of various PIs (amprenavir, indinavir, nelfinavir, ritonavir, and saquinavir) and synthetic retinoids, and the metabolic response was assessed by measuring the activity of a retinoid-regulated protein, alkaline phosphatase (ALP). Of the PIs tested, only indinavir stimulated ATRA-dependent ALP activity and altered stem cell morphology; the effects of indinavir occurred in the presence of ATRA, but not in its absence. Moreover, indinavir increased the effects of ATRA on lipid accumulation during far cell differentiation. AGN 193109 (4-[[5,6-dihydro-5,5-dimethyl-8-(4-methylphenyl)-2-naphthalenyl]ethynyl]-benzoic acid), a retinoic acid receptor (RAR) antagonist, inhibited the synergistic effects of indinavir and ATRA, indicating that indinavir increases RAR signaling. However, indinavir did not potentiate ALP activity in the presence of the RAR agonist CH55 (3,5-di-tert-butylchalcone 4'-carboxylic acid). Unlike ATRA, CH55 does nor bind to cytosolic retinoic acid binding protein (CRABP), suggesting that CRABP may regulate the effects of indinavir on RAR signaling. These observations support the proposal that altered retinoid signaling promotes some of the adverse reactions associated with indinavir therapy, such as altered lipid metabolism. (C) 2000 Elsevier Science Inc.
引用
收藏
页码:1063 / 1068
页数:6
相关论文
共 33 条
[1]  
Balani SK, 1996, DRUG METAB DISPOS, V24, P1389
[2]  
Behrens G, 1998, LANCET, V351, P1958, DOI 10.1016/S0140-6736(98)26026-0
[3]   DESIGN AND SYNTHESIS OF POTENT RETINOID-X RECEPTOR-SELECTIVE LIGANDS THAT INDUCE APOPTOSIS IN LEUKEMIA-CELLS [J].
BOEHM, MF ;
ZHANG, L ;
ZHI, L ;
MCCLURG, MR ;
BERGER, E ;
WAGONER, M ;
MAIS, DE ;
SUTO, CM ;
DAVIES, PJA ;
HEYMAN, RA ;
NADZAN, AM .
JOURNAL OF MEDICINAL CHEMISTRY, 1995, 38 (16) :3146-3155
[4]   Paronychia and pyogenic granuloma of the great toes in patients treated with indinavir [J].
Bouscarat, F ;
Bouchard, C ;
Bouhour, D .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (24) :1776-1777
[5]   Alopecia associated with indinavir therapy [J].
Bouscarat, F ;
Prevot, MH ;
Matheron, S .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (08) :618-618
[6]   Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance [J].
Carr, A ;
Samaras, K ;
Chisholm, DJ ;
Cooper, DA .
LANCET, 1998, 351 (9119) :1881-1883
[7]   An audit of place of death of cancer patients in a semi-rural Scottish practice [J].
Carroll, DS .
PALLIATIVE MEDICINE, 1998, 12 (01) :51-53
[8]   A SHORT-TERM STUDY OF THE SAFETY, PHARMACOKINETICS, AND EFFICACY OF RITONAVIR, AN INHIBITOR OF HIV-1 PROTEASE [J].
DANNER, SA ;
CARR, A ;
LEONARD, JM ;
LEHMAN, LM ;
GUDIOL, F ;
GONZALES, J ;
RAVENTOS, A ;
RUBIO, R ;
BOUZA, E ;
PINTADO, V ;
AGUADO, AG ;
DELOMAS, JG ;
DELGADO, R ;
BORLEFFS, JCC ;
HSU, A ;
VALDES, JM ;
BOUCHER, CAB ;
COOPER, DA ;
GIMENO, C ;
CLOTET, B ;
TOR, J ;
FERRER, E ;
MARTINEZ, PL ;
MORENO, S ;
ZANCADA, G ;
ALCAMI, J ;
NORIEGA, AR ;
PULIDO, F ;
GLASSMAN, HN .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (23) :1528-1533
[9]  
GOLD EJ, 1983, CANCER TREAT REP, V67, P981
[10]  
GRUNFELD C, 1991, AM J MED, V90, P154, DOI 10.1016/0002-9343(91)80154-E